Trending

CNS

Regeneron and Alnylam announce $1bn collaboration

Regeneron and Alnylam announce $1bn collaboration

Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and

X

Regeneron and Alnylam announce $1bn collaboration

https://pharmaphorum.com/news/regeneron-and-alnylam-announce-1bn-collaboration/

Pfizer’s CNS exit takes the form of a biotech spinout

Pfizer’s CNS exit takes the form of a biotech spinout

Pfizer’s plans to duck out of central nervous system R&D have come to fruition, with the creation of

X

Pfizer’s CNS exit takes the form of a biotech spinout

https://pharmaphorum.com/news/pfizers-cns-exit-takes-the-form-of-a-biotech-spinout/

Tysabri failure in stroke a setback for Biogen

Tysabri failure in stroke a setback for Biogen

Biogen’s hopes that one of its established multiple sclerosis drugs might also help stroke sufferers have been dashed.

X

Tysabri failure in stroke a setback for Biogen

https://pharmaphorum.com/news/tysabri-failure-stroke-setback-biogen/

Looking back, looking forward – Janssen’s 60 years on the psychiatry horizon

Looking back, looking forward – Janssen’s 60 years on the psychiatry horizon

Improving targeted treatments and partnering on initiatives to reduce stigma and support mental health patients.

X

Looking back, looking forward – Janssen’s 60 years on the psychiatry horizon

https://pharmaphorum.com/views-and-analysis/janssen-mental-health-psychiatry/

Ex-Novartis chief Epstein joins Remedy Pharmaceuticals

Ex-Novartis chief Epstein joins Remedy Pharmaceuticals

David Epstein, who left his job as head of Novartis’ pharma division in May, has joined Remedy Pharmaceuticals

X

Ex-Novartis chief Epstein joins Remedy Pharmaceuticals

https://pharmaphorum.com/news/ex-novartis-chief-epstein-joins-remedy-pharmaceuticals/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com